76950 Federal Register / Vol. 69, No. 246 / Thursday, December 23, 2004 / Notices 

proliferative peptides, methods for 

making such compounds, and methods 

for using these compounds for the 

treatment of hyper-proliferative diseases 

such as cancer or psoriasis. A current 

limitation on cancer therapy is that 

therapeutic agents may not target tumor 

cells specifically or enter the cells 

efficiently. A strategy that combines the 

therapeutic agent with a moiety that 

mediates cellular entry is one method to 

overcome this limitation. However, the 

efficacy of the therapeutic agent within 

the cells can be reduced by the linkage 

to the moiety that mediates cellular 

entry. The compounds of the current 

invention are designed to enter cells 

efficiently, and upon entry, to uncouple 

the therapeutic agent from the cellular 

targeting moiety. 

Rottlerin, a protein kinase C inhibitor, 

selectively induces apoptosis of 

metastasized melanoma cells of 

epithelial morphology (DHHS Ref. No. 

E–311–2003), and is a potential 

therapeutic agent. Peptides derived from 

the known tumor suppressor genes H–

Ha–Rev107 and H–TIG3, that are 

homologous to a peptide of LRAT 

(lecithin:retinol acyl transferase) cross 

the cell membrane and localize to the 

nucleus. These peptides, which inhibit 

the growth of melanoma cells (described 

in DHHS Ref. No. E–052–2002), could 

also serve as intracellular delivery 

agents. 

The current invention discloses a 

novel composition of rottlerin and 

LRAT peptide (named LRATlerin). 

LRATlerin is designed so that the LRAT 

peptide can release the rottlerin upon 

cellular entry. LRATlerin has enhanced 

properties not exhibited by rottlerin or 

the peptide alone including the ability 

to induce apoptosis of primary site and 

metastasized tumor cells that are 

epithelioid or fibroblastoid, without 

apparent toxicity normal healthy cells. 

Thus, the compositions of the current 

invention have the potential to be 

highly effective therapies for 

proliferative diseases. 

Modulating Expression of the 

Metastasis Suppressor MxA 

Jane B. Trepel et al. (NCI) 

DHHS Reference No. E–257–2004/0–

US–01 (U.S. Provisional Patent 

Application) 

Licensing Contact: Mojdeh Bahar; 301/

435–2950; baharm@mail.nih.gov.

The invention discloses compounds 

that could be used to inhibit metastases. 

The compounds of the current invention 

were discovered by high-throughput 

screening of a novel cell line engineered 

with a MxA reporter. The compounds 

could be used to treat metastatic cancers 

including prostate and melanomas by 

increasing MxA expression. 

MxA expression reduces cell motility 

and metastases in a mouse model. Cells 

expressing MxA produced smaller 

tumors in engrafted mice compared to 

controls. When injected into mouse 

spleens, cells expressing MxA showed a 

significantly delayed metastasis, and the 

mice survived significantly longer than 

controls. Expression of MxA reduced 

cellular motility of prostate cancer cell 

lines in vitro and reduced cellular 

motility and invasiveness of the highly 

metastatic melanoma cell line LOX. 

Background information for this 

technology can be found in DHHS 

Reference No. E–292–2001. 

In addition to licensing, the 

technology is available for further 

development through collaborative 

research with the inventors via a 

Cooperative Research and Development 

Agreement (CRADA). 

Modified Myelin Basic Protein 

Molecules 

Michael J. Lenardo et al. (NIAID) 

DHHS Ref. No. E–033–1996/0–US–01

Licensing Contact: Mojdeh Bahar; 

301/435–2950; baharm@mail.nih.gov.

This invention is directed to 

compositions and methods for clinical 

assessment, diagnosis and treatment of 

Multiple Sclerosis (MS). The 

compositions are molecules related to 

the 21.5 kDA fetal isoform of human 

myelin basic protein (MBP), and include 

nucleic acids and polypeptides. The 

nucleic acids are useful in the efficient 

production of modified and unmodified 

MBP polypeptides and the polypeptides 

are useful for assaying T cells for 

responsiveness to MBP epitopes. They 

are further useful as therapeutic agents 

that act by inducing T cell responses, 

including apoptosis, as a means of 

treating MS. 

Modified Proteolipid Protein Molecules 

Michael J. Lenardo et al. (NIAID) 

DHHS Ref. No. E–128–1996/1–US–01

Licensing Contact: Mojdeh Bahar; 301/

435–2950; baharm@mail.nih.gov.

This invention is directed to 

compositions and methods for clinical 

assessment, diagnosis and treatment of 

Multiple Sclerosis (MS). The 

compositions are molecules related to 

the human proteolipid protein (PLP), 

and include nucleic acids and 

polypeptides. The nucleic acids are 

useful in the production of modified 

PLP polypeptides and the polypeptides 

are useful for assaying T cells for 

responsiveness to PLP epitopes. They 

are further useful as therapeutic agents 

that act by inducing T cell responses, 

including apoptosis, as a means of 

treating MS.

Dated: December 15, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–28068 Filed 12–22–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

Proposed Collection; Comment 

Request Certificate of Compliance for 

Turbine Fuel Withdrawals

ACTION: Notice and request for 

comments. 

SUMMARY: As part of its continuing effort 

to reduce paperwork and respondent 

burden, Bureau of Customs and Border 

Protection (CBP) invites the general 

public and other Federal agencies to 

comment on an information collection 

requirement concerning the Certificate 

of Compliance for Turbine Fuel 

Withdrawals. This request for comment 

is being made pursuant to the 

Paperwork Reduction Act of 1995 (Pub. 

L. 104–13; 44 U.S.C. 3505(c)(2)).

DATES: Written comments should be 

received on or before February 22, 2005, 

to be assured of consideration.

ADDRESSES: Direct all written comments 

to Bureau of Customs and Border 

Protection, Information Services Group, 

Attn.: Tracey Denning, 1300 

Pennsylvania Avenue, NW., Room 3.2C 

Washington, DC 20229.

FOR FURTHER INFORMATION CONTACT:

Requests for additional information 

should be directed to Bureau of Customs 

and Border Protection, Attn. Tracey 

Denning, 1300 Pennsylvania Avenue 

NW., Room 3.2C, Washington, DC 

20229, Tel. (202) 344–1429.

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). The comments 

should address: (a) Whether the 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimates of the burden of the 

collection of information; (c) ways to 

enhance the quality, utility, and clarity 

Federal Register / Vol. 69, No. 246 / Thursday, December 23, 2004 / Notices 76951

of the information to be collected; (d) 

ways to minimize the burden including 

the use of automated collection 

techniques or the use of other forms of 

information technology; and (e) 

estimates of capital or start-up costs and 

costs of operations, maintenance, and 

purchase of services to provide 

information. The comments that are 

submitted will be summarized and 

included in the CBP request for Office 

of Management and Budget (OMB) 

approval. All comments will become a 

matter of public record. In this 

document CBP is soliciting comments 

concerning the following information 

collection: 

Title: Certificate of Compliance for 

Turbine Fuel Withdrawals. 

OMB Number: 1651–0072. 

Form Number: N/A. 

Abstract: This information is 

collected to ensure regulatory 

compliance for Turbine Fuel 

Withdrawals to protect revenue 

collections. 

Current Actions: There are no changes 

to the information collection. This 

submission is being submitted to extend 

the expiration date. 

Type of Review: Extension. 

Affected Public: Businesses, 

Institutions. 

Estimated Number of Respondents:

30. 

Estimated Time Per Respondent: 12 

hours. 

Estimated Total Annual Burden 

Hours: 360. 

Estimated Total Annualized Cost on 

the Public: $14,916.

Dated: December 16, 2004. 

Tracey Denning, 

Agency Clearance Officer, Information 

Services Branch.

[FR Doc. 04–28069 Filed 12–22–04; 8:45 am] 

BILLING CODE 4820–02–P

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

Proposed Collection; Comment 

Request; Request for Information

ACTION: Notice and request for 

comments. 

SUMMARY: As part of its continuing effort 

to reduce paperwork and respondent 

burden, the Bureau of Customs and 

Border Protection (CBP) invites the 

general public and other Federal 

agencies to comment on an information 

collection requirement concerning 

Request for Information. This request for 

comment is being made pursuant to the 

Paperwork Reduction Act of 1995 (Pub. 

L. 104–13; 44 U.S.C. 3505(c)(2)).

DATES: Written comments should be 

received on or before February 22, 2005, 

to be assured of consideration.

ADDRESSES: Direct all written comments 

to Bureau of Customs and Border 

Protection, Information Services Group, 

Attn.: Tracey Denning, 1300 

Pennsylvania Avenue, NW., Room 3.2C, 

Washington, DC 20229.

FOR FURTHER INFORMATION CONTACT:

Requests for additional information 

should be directed to Bureau of Customs 

and Border Protection, Attn.: Tracey 

Denning, 1300 Pennsylvania Avenue 

NW., Room 3.2C, Washington, DC 

20229, Tel. (202) 344–1429.

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). The comments 

should address: (a) Whether the 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimates of the burden of the 

collection of information; (c) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; (d) 

ways to minimize the burden including 

the use of automated collection 

techniques or the use of other forms of 

information technology; and (e) 

estimates of capital or start-up costs and 

costs of operations, maintenance, and 

purchase of services to provide 

information. The comments that are 

submitted will be summarized and 

included in the CBP request for Office 

of Management and Budget (OMB) 

approval. All comments will become a 

matter of public record. In this 

document CBP is soliciting comments 

concerning the following information 

collection: 

Title: Request for Information. 

OMB Number: 1651–0023. 

Form Number: Form CBP–28. 

Abstract: Form CBP–28 is used by 

CBP personnel to request additional 

information from importers when the 

invoice or other documentation provide 

insufficient information for CBP to carry 

out its responsibilities to protect 

revenues. 

Current Actions: There are no changes 

to the information collection. This 

submission is being submitted to extend 

the expiration date. 

Type of Review: Extension. 

Affected Public: Businesses, 

Individuals, Institutions. 

Estimated Number of Respondents:

60,000. 

Estimated Time Per Respondent: 1 

hour. 

Estimated Total Annual Burden 

Hours: 60,000. 

Estimated Total Annualized Cost on 

the Public: N/A.

Dated: December 16, 2004. 

Tracey Denning, 

Agency Clearance Officer, Information 

Services Group.

[FR Doc. 04–28070 Filed 12–22–04; 8:45 am] 

BILLING CODE 4820–02–P

DEPARTMENT OF HOMELAND 

SECURITY 

Bureau of Customs and Border 

Protection 

Proposed Collection; Comment 

Request; Establishment of a Container 

Station

ACTION: Notice and request for 

comments. 

SUMMARY: As part of its continuing effort 

to reduce paperwork and respondent 

burden, Bureau of Customs and Border 

Protection (CBP) invites the general 

public and other Federal agencies to 

comment on an information collection 

requirement concerning Establishment 

of a Container Station. This request for 

comment is being made pursuant to the 

Paperwork Reduction Act of 1995 (Pub. 

L. 104–13; 44 U.S.C. 3505(c)(2)).

DATES: Written comments should be 

received on or before February 22, 2005, 

to be assured of consideration.

ADDRESSES: Direct all written comments 

to Bureau of Customs and Border 

Protection, Information Services Group, 

Attn.: Tracey Denning, 1300 

Pennsylvania Avenue, NW., Room 3.2C, 

Washington, DC 20229.

FOR FURTHER INFORMATION CONTACT:

Requests for additional information 

should be directed to Bureau of Customs 

and Border Protection, Attn.: Tracey 

Denning, 1300 Pennsylvania Avenue 

NW., Room 3.2C, Washington, DC 

20229, Tel. (202) 344–1429.

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13; 

44 U.S.C. 3505(c)(2)). The comments 

should address: (a) Whether the 

collection of information is necessary 

for the proper performance of the